Date: 2016-06-03
Type of information: Collaboration agreement
Compound: dolutegravir
Company: ViiV Healthcare (UK - USA) Botswana Ministry of Health
Therapeutic area: Infectious diseases
Type agreement: collaboration
Action mechanism: integrase inhibitor/enzyme inhibitor. Dolutegravir is an investigational integrase inhibitor (INI). INI blocks HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle and is also responsible for establishing chronic infection.
Disease: HIV infection
Details: * On June 3, 2016, ViiV Healthcare confirmed a public tender agreement with the Ministry of Health in Botswana to support the implementation of a new national ‘Treat All’ programme which aims to ensure people living with HIV in the country get tested and receive treatment. This is the first time dolutegravir will be made available as part of a national health programme in sub-Saharan Africa since the WHO recommended dolutegravir as alternative first line treatment in HIV patients in late 2015. As part of the agreement, ViiV Healthcare has committed to providing dolutegravir 50mg. The medicine would be used as a first linecore-agent to treat newly diagnosed patients tested under the programme in Botswana. The public tender agreement has resulted from positive negotiations with the Botswana Government and is the latest project in a series of initiatives undertaken by ViiV Healthcare to support the response to the HIV epidemic across Africa. It follows two other recent announcements, including the company’s involvement in a new national programme launched in Lesotho to double the number of children at risk of HIV in care and on treatment in the country within three years.
Financial terms:
Latest news:
